Author

Hisatomo Kowa

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Baseline CSF tau and short‐term clinical change during lecanemab therapy: A prospective real‐world cohort study in Japan

Abstract INTRODUCTION Real‐world prognostic evidence for cerebrospinal fluid (CSF) biomarkers during lecanemab therapy remains limited. We examined whether baseline CSF phosphorylated tau 181 (pTau181), total tau, and amyloid beta (Aβ) 42/Aβ40 were associated with 6‐month clinical change. METHODS This prospective singl...

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · Alzheimer's & Dementia · 0 citations

Sep 2026

Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

Amyloid-related imaging abnormalities (ARIA) are a safety concern during lecanemab treatment for early Alzheimer's disease. We examined baseline cerebrospinal fluid amyloid-β 42 (Aβ42) in 97 lecanemab-treated patients; 11 developed ARIA. Aβ42 was lower in ARIA cases than in non-ARIA cases (483.2 ± 108.6 versus 667.4 ± ...

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · Journal of Alzheimer's Disea... · 0 citations